# EDGAR Filing Document

**Accession Number:** 0001623715
**File Stem:** 0001193125-23-006154
**Filing Date:** 2023-1
**Character Count:** 5798
**Document Hash:** 716b2c46ce3b661b3395f204c2948198
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-006154.hdr.sgml**: 20230111

**ACCESSION NUMBER**: 0001193125-23-006154

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230111

**DATE AS OF CHANGE**: 20230111

**EFFECTIVENESS DATE**: 20230111

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Imago BioSciences, Inc.
- **CENTRAL INDEX KEY:** 0001623715
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 454915810
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-258057
- **FILM NUMBER:** 23522668

**BUSINESS ADDRESS:**
- **STREET 1:** 303 TWIN DOLPHIN DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** (415) 529-5055

**MAIL ADDRESS:**
- **STREET 1:** 303 TWIN DOLPHIN DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**As filed with the Securities and Exchange Commission on January 11, 2023** 

**Registration No. 333-258057** 

**Registration No. 333-263828** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**POST-EFFECTIVE AMENDMENT NO. 1** 

**TO** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

**THE SECURITIES ACT OF 1933** 

------

## IMAGO BIOSCIENCES, INC.
**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **45-4915810** |
| **(State or other jurisdiction of incorporation)** | **(I.R.S. Employer Identification Number)** |

---

**2012 Equity Incentive Plan** 

**2021 Incentive Award Plan** 

**2021 Employee Stock Purchase Plan** 

**(Full title of the plan)** 

------

**Kelly E.W. Grez, Secretary** 

**Imago BioSciences, Inc.** 

**303 Twin Dolphin Drive, 6th Floor** 

**Redwood City, California 94065** 

**(415) 529-5055** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

------

***Copy to:***

**Saee Muzumdar** 

**Gibson, Dunn & Crutcher LLP** 

**200 Park Avenue** 

**New York, NY 10166-0193** 

**(212) 351-4035** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**<u>TERMINATION OF REGISTRATION</u>**

This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (each, a "Registration Statement" and collectively, the "Registration Statements") filed by Imago BioSciences, Inc. (the "Company") with the Securities and Exchange Commission:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. 333-258057, filed on July 21, 2021,
registering 3,171,061 shares of common stock under the Company's 2012 Equity Incentive Plan, 3,450,000 shares of common stock under the Company's 2021 Incentive Award Plan, and 350,000 shares of common stock under the Company's 2021
Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. 333-263828, filed on March 24, 2022,
registering 1,676,587 shares of common stock under the Company's 2021 Incentive Award Plan, and 335,317 shares of common stock under the Company's 2021 Employee Stock Purchase Plan.

Pursuant to the Agreement and Plan of Merger, dated as of November 19, 2022 (the "Merger Agreement"), by and among the Company, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and M-Inspire Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Company has terminated all offerings of its securities pursuant to the Registration Statements and hereby removes and withdraws from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rahway, in the State of New Jersey, on this 11th day of January, 2023.

---

| | |
|:---|:---|
| **IMAGO BIOSCIENCES, INC. (REGISTRANT)** | **IMAGO BIOSCIENCES, INC. (REGISTRANT)** |
| By: | /s/ Kelly E.W. Grez |
| Name: | Kelly E.W. Grez |
| Title: | Secretary |

---

Pursuant to the Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment to Registration Statements.